# CJC-1295 FAQ: Safety, Status, and the Research Record > CJC-1295 FAQ: is it FDA approved, is it safe, is it a steroid, what are the side effects. Direct, cited answers from the published GHRH-analog research record. Direct answers to the most-asked questions, each logged to the published literature — including the amber-flagged status lines where the answer is a regulatory boundary. ## Is CJC-1295 FDA approved? No. CJC-1295 is not approved for human use anywhere. It was reviewed and not recommended for the FDA 503A compounding bulks list at the 2024 Pharmacy Compounding Advisory Committee [1]. It is handled as a research chemical, not a medicine. ## Is CJC-1295 safe? CJC-1295 is an unapproved research chemical with no large human safety trials [1]. Theoretical concerns include fluid retention from GH-driven sodium reabsorption [12], effects on insulin sensitivity, and sustained IGF-1 elevation, which epidemiology links to a modestly higher risk of some cancers [1]. The honest answer is that the safety question is open. ## Are CJC-1295 peptides safe? CJC-1295 is an unapproved research peptide with no large human safety trials [1]. Documented and theoretical concerns include fluid retention [12], effects on insulin sensitivity, immunogenicity flagged in 2024 FDA PCAC materials, and the cancer-risk epidemiology tied to sustained IGF-1 elevation [1]. No controlled trial has established an adverse-event profile for the compound. ## What are the side effects of CJC-1295? Reported and theoretical concerns include fluid retention and edema, via GH-driven renal sodium reabsorption [12]; effects on insulin sensitivity; injection-site reactions; and open questions around immunogenicity and sustained IGF-1 elevation [1]. None is a measured adverse-event rate from a controlled CJC-1295 trial — they are the safety signals the thin evidence base leaves unresolved. ## Is CJC-1295 a steroid? No. CJC-1295 is a peptide GHRH analog — a growth-hormone secretagogue — not an anabolic-androgenic steroid [2]. It acts on the GHRH receptor on pituitary cells rather than the androgen receptor, working through the GH/IGF-1 axis [3]. ## Does CJC-1295 affect testosterone? CJC-1295 acts on the GH/IGF-1 axis, not the gonadal axis; there is no established direct effect on testosterone in the published human literature [3]. Claims in either direction are not supported by controlled data. The compound's measured effects are on GH and IGF-1, not sex steroids [1]. ## Does CJC-1295 lower testosterone? No published human data show that CJC-1295 lowers testosterone. It operates on the GHRH/GH/IGF-1 pathway rather than the hypothalamic-pituitary-gonadal axis [3]. There is no controlled evidence of a suppressive effect on testosterone. ## Are peptides like CJC-1295 safer than TRT? This cannot be answered from the evidence. CJC-1295 is unapproved with thin human safety data, whereas testosterone replacement is a regulated therapy with established monitoring [1]. They act on entirely different axes — the GH/IGF-1 axis versus the gonadal axis — and are not interchangeable. No head-to-head safety comparison exists. ## What is CJC-1295 ipamorelin? CJC-1295 / ipamorelin is a commonly studied pairing of a GHRH analog (CJC-1295) with a selective GH secretagogue (ipamorelin), combining two complementary GH-release pathways [3]. It is a combination of two compounds, not the single peptide. Controlled efficacy data for the specific pairing in healthy adults are lacking [1]. ## How much CJC-1295 / ipamorelin should I take? No validated human dose exists for the combination. The pairing rests on a two-receptor rationale, but the doses circulated online are not derived from controlled human trials [1]. This site does not provide human-use dosing for the compound or the combination. ## What is the regulatory and anti-doping status of CJC-1295? CJC-1295 is unapproved for human use anywhere and was not recommended for the FDA 503A compounding bulks list at the 2024 Pharmacy Compounding Advisory Committee [1]. In sport, it is prohibited at all times under WADA Section S2 and is banned by bodies such as the NCAA, with established detection assays [6]. Its identity has been confirmed by LC-MS/MS in seized preparations [6]. ## CJC-1295 Side Effects and Safety Signals in the Literature The CJC-1295 side effects and safety signals in the literature are class-level and largely theoretical, because the compound has no large human safety trial [1]. Growth hormone increases extracellular fluid volume by stimulating sodium reabsorption in the distal nephron, the documented mechanism behind GH-axis fluid retention and edema [12]. Sustained IGF-1 elevation is the second flagged signal: holding IGF-1 above baseline for weeks is theoretically relevant to the epidemiological link between higher IGF-1 and certain cancers [1]. The 2024 FDA Pharmacy Compounding Advisory Committee cited immunogenicity and other safety concerns for GH secretagogues including CJC-1295 when it declined to recommend the class for the 503A bulks list [1]. Effects on insulin sensitivity are plausible given GH's counter-regulatory action on glucose, and injection-site reactions are a route-level consideration [1]. Regulatory status is itself a safety-relevant fact: CJC-1295 is prohibited at all times in sport under WADA Section S2 and is banned by bodies such as the NCAA [6]. The clearest lines in the record are these flagged ones — unapproved, immunogenicity-flagged, IGF-1-watched, and prohibited in competition — not a list of demonstrated benefits. --- A flight-log read of the CJC-1295 record — measured telemetry where the studies exist, flagged gaps where they stop, no clinic behind the console and nothing here dispensed or sold.